Showing results (711-720 of 6,765) with videos related to
Sort By:
Pageof 677
Clinical Therapeutics|August 4, 2012
Bioavailability and tolerability of combination treatment with revaprazan 200 mg + itopride 150 mg: a randomized crossover study in healthy male Korean volunteersHee Youn Choi, Yook-Hwan Noh, Seok-Joon Jin, et al.Clinical Therapeutics|August 3, 2012
I-ADD study: assessment of efficacy and safety profile of irbesartan/amlodipine fixed-dose combination therapy compared with irbesartan monotherapy in hypertensive patients uncontrolled with irbesartan 150 mg monotherapy: a multicenter, phase III, prospective, randomized, open-label with blinded-end point evaluation studyGuillaume Bobrie, Clinical Therapeutics|August 25, 2012
Effects of a supratherapeutic dose of investigational orally inhaled dihydroergotamine (MAP0004) on QT interval: a randomized, double-blind, active- and placebo-controlled crossover study in healthy volunteersShashidhar Kori, Donald J Kellerman, Polina Voloshko, et al.Clinical Therapeutics|November 1, 1990
A comparison of the efficacy and tolerability of enalapril and sustained-release diltiazem in mild to moderate essential hypertensionM R Weir, R Haynie, V Vertes, et al.Clinical Therapeutics|August 22, 2012
Long-term cost-effectiveness model of interferon beta-1b in the early treatment of multiple sclerosis in the United StatesFeng Pan, Jo Wern Goh, Gary Cutter, et al.Clinical Therapeutics|April 28, 2004
A single-blind, randomized, controlled trial to assess the efficacy and tolerability of rofecoxib, diclofenac sodium, and meloxicam in patients with acute gouty arthritisTien-Tsai Cheng, Han-Ming Lai, Chun-Kai Chiu, et al.Clinical Therapeutics|September 1, 1992
Blood and urinary magnesium kinetics after oral magnesium supplementsJ White, L Massey, S K Gales, et al.Clinical Therapeutics|March 25, 2004
Progress with thiazolidinediones in the management of type 2 diabetes mellitusTerry MeridenPageof 677